Health Journalists Spotlight Rural Health Sentiment, MAHA Movement, and Gene-Editing Advances October 3, 2026 KFF Health News journalists appeared across major broadcast networks and public radio in late September, covering a diverse range of health policy topics from rural voter sentiment to cutting-edge gene-editing…
Health Eli Lilly’s Combination Obesity Drug Achieves 23% Weight Loss in Diabetic Patients, Surpassing Zepbound October 1, 2026 Eli Lilly has announced groundbreaking results for its experimental combination obesity treatment, reporting that eloraTZP achieved 23.3% average weight loss in patients battling both obesity or overweight and type 2…
Science Novo Nordisk Sues Eli Lilly Over Allegedly Misleading Weight-Loss Drug Advertising July 21, 2026 Novo Nordisk filed a lawsuit Tuesday against Eli Lilly in U.S. District Court for the District of New Jersey, accusing its American rival of running misleading advertising campaigns for blockbuster…
Health One in Ten Americans Now Takes GLP-1 Drugs for Weight Loss as Obesity Rate Drops July 8, 2026 GLP-1 Medication Use Surges Among American Adults The percentage of U.S. adults who currently take GLP-1 medications for weight loss purposes has risen to 11% in 2026, up significantly from…
Health CVS Health Restores Zepbound Coverage After Landmark Pricing Deal May 28, 2026 Major Shift in Weight-Loss Drug Coverage CVS Health announced Thursday it will restore coverage for Eli Lilly’s weight-loss drug Zepbound on select formularies. The pharmacy giant will add the treatment…